Protocol Ledger

NCT03952143 · Phase III · COMPLETED

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes

Interventional Phase III clinical trial protocol NCT03952143 sponsored by Eli Lilly and Company in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-27 Enrollment: 628 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03952143
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)628 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03952143
Protocol FieldVerified Registry Value
NCT IdentifierNCT03952143
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment628 participants (ACTUAL)
Registered Start Date2019-05-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03952143
Hospital Research SiteLocationSite Profile
Tianjin Medical University General HospitalTianjin, ChinaOpen Hospital Dossier ->
Shengjing hospital of China medical universityShenyang, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI